Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12
06 October 2022 - 7:30AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune
disease, today announced it will present a poster on its
bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC’s
37th Annual Meeting being held November 8th – 12th, 2022,
virtually and in-person in Boston.
Presentation DetailsAbstract Title: Antigen
targeted butyrophilin heterodimer-based bispecific engagers induce
Vγ9δ2+ T cell-mediated anti-tumor activityAbstract Number:
1203Presenters: Suresh de Silva, Ph.D., Vice President of
Product Development at Shattuck Labs and Derek
Franklin, Ph.D., Scientist III at Shattuck LabsDate: November
10th Location: Boston, MAPoster Hall Hours: 9:00 a.m. to 9:00 p.m.
ET
Further information about the Society for Immunotherapy of
Cancer Meeting can be found
at:https://www.sitcancer.org/2022/home
About Shattuck Labs, Inc.Shattuck Labs, Inc.
(NASDAQ: STTK) is a clinical-stage biotechnology company pioneering
the development of bi-functional fusion proteins as a new class of
biologic medicine for the treatment of patients with cancer and
autoimmune disease. Compounds derived from Shattuck’s proprietary
Agonist Redirected Checkpoint, ARC®, platform simultaneously
inhibit checkpoint molecules and activate costimulatory molecules
with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L)
program, which is designed to block the CD47 immune checkpoint and
simultaneously agonize the CD40 pathway, is being evaluated in
multiple Phase 1 trials. A second product candidate, SL-279252
(PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid
tumors or lymphomas. Additionally, the company is advancing a
proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is
designed to bridge gamma delta T cells to tumor antigens for the
treatment of patients with cancer. Shattuck has offices in both
Austin, Texas and Durham, North Carolina. For more information,
please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its
website as a means of disclosing material non-public information
and for complying with disclosure obligations under Regulation
FD.
Investor Contact: Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024